KCT0001100招募中未知
A Multi-center, Randomized, Double-blind, Comparative Study to Evaluate the Efficacy between Helicobacter pylori Eradication Therapy and Motilitone in Functional Dyspepsia
Chung-Ang Univerisity Hospital0 个研究点目标入组 138 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 138
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 20(Year) 至 70(Year)（—）
- 性别
- All
入选标准
- •1) patients of age 20 to 70
- •2) the patients with functional dyspepsia met the Rome III criteria
排除标准
- •1) Pregnant or lactating women, child bearing women not using a proper contraception
- •2) Patients with previous gastrointestinal surgery
- •3) Patients with history of gastrointestinal bleeding, mechanical obstruction, perforation
- •4) who had bowel symptoms suggestive of irritable bowel syndrome (Rome III criteria)
- •5)who had reflux esophagitis, peptic ulcers (active or healing stage), gastric adenocarcinoma, esophageal carcinoma, pancreatic disease(pancreatitis, pancreatic cancer, etc), biliary disease, inflammatory bowel disease during recent 6 months
- •6) previous eradication therapy for H. pylori
- •7) uncontrolled diabetes mellitus and hypertension
- •8) hepatic abnormality (more than 3 folds of upper normal limit in AST(Aspartate Aminotransferase)/ALT(Alanine Aminotransferase)
- •9) renal dysfunction (more than 2 folds of upper normal limit in serum creatinine
- •10) severe disease for heart, lung, hematology, and endocrine system
- •11) alcoholism, psycosis, neurosis, drug addiction status
- •12)who were treated by histamine-receptor antagonists,proton pump inhibitors, prostaglandins, prokinetics, bismuthcontaining compounds, or antibiotics during 2 weeks before the study began
- •13) Allergic disease for experimental medicine
研究者
相似试验
进行中（未招募）
1 期
A clinical trial to evaluate the safety and efficacy of ZTI-01 versus Piperacillin/Tazobactam in hospitalized patients with complicated urinary tract infections.Complicated Urinary Tract Infections, Including Acute PyelonephritisMedDRA version: 19.0Level: PTClassification code 10037597Term: Pyelonephritis acuteSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 19.0Level: HLTClassification code 10046577Term: Urinary tract infectionsSystem Organ Class: 10021881 - Infections and infestationsEUCTR2015-003372-73-GRZavante Therapeutics, Inc.460
进行中（未招募）
1 期
A clinical trial to evaluate the safety and efficacy of ZTI-01 versus Piperacillin/Tazobactam in hospitalized patients with complicated urinary tract infections.EUCTR2015-003372-73-ROZavante Therapeutics, Inc.460
进行中（未招募）
1 期
A clinical trial to evaluate the safety and efficacy of ZTI-01 versus Piperacillin/Tazobactam in hospitalized patients with complicated urinary tract infections.Complicated Urinary Tract Infections, Including Acute PyelonephritisMedDRA version: 19.1Level: PTClassification code 10037597Term: Pyelonephritis acuteSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 19.1Level: HLTClassification code 10046577Term: Urinary tract infectionsSystem Organ Class: 10021881 - Infections and infestationsEUCTR2015-003372-73-PLZavante Therapeutics, Inc.460
进行中（未招募）
1 期
A clinical trial to evaluate the safety and efficacy of ZTI-01 versus Piperacillin/Tazobactam in hospitalized patients with complicated urinary tract infections.Complicated Urinary Tract Infections, Including Acute PyelonephritisMedDRA version: 19.0Level: PTClassification code 10037597Term: Pyelonephritis acuteSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 19.0Level: HLTClassification code 10046577Term: Urinary tract infectionsSystem Organ Class: 10021881 - Infections and infestationsEUCTR2015-003372-73-BGZavante Therapeutics, Inc.460
进行中（未招募）
1 期
A clinical trial to evaluate the safety and efficacy of ZTI-01 versus Piperacillin/Tazobactam in hospitalized patients with complicated urinary tract infections.EUCTR2015-003372-73-CZZavante Therapeutics, Inc.460